Company: INTS
Filing Date: 2025-04-24
Form Type: S-1/A
Source: 0001628280-25-019491
Chunk: 57

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: S-1/A
Chunk 57
---
 agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering. We may not sell the entire amount of securities offered pursuant to this prospectus supplement. The Placement Agents may retain sub-agents and selected dealers in connection with this offering.

We expect this offering to be completed not later than one business day following the commencement of the offering and we will deliver the securities being issued to each investor upon receipt of such investor’s funds for the purchase of the securities offered pursuant to this prospectus and we will deliver all securities to be issued in connection with this offering delivery versus payment (DVP)/receipt versus payment (RVP) upon receipt of investor funds received by us. We expect to deliver the securities being offered pursuant to this prospectus on or about , 2025, subject to satisfaction of certain conditions.

We have agreed to indemnify the Placement Agents against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the Placement Agents may be required to make in respect thereof.

#### Fees and Expenses
We have agreed to pay the Placement Agents an aggregate fee equal to seven percent (7.0%) of the purchase price paid by all purchasers in this offering. In addition, we have agreed to reimburse the Placement Agents for their legal fees in an amount up to $80,000 and non-accountable expenses of up to $25,000.

The following table shows the per share and total cash fees we will pay to the Placement Agents in connection with the sale of the securities pursuant to this prospectus.

|                                   |     | Per Share ofCommon StockandAccompanyingCommonWarrants |     | Per Pre-FundedWarrant andAccompanyingCommonWarrants |     | Total |
|:----------------------------------|:----|:------------------------------------------------------|:----|:----------------------------------------------------|:----|:------|
| Public offering price(1)          |     | $                                                     |     | $                                                   |     | $     |
| Placement Agents’ fees            |     | $                                                     |     | $                                                   |     | $     |
| Proceeds before expenses to us(2) |     | $                                                     |     | $                                                   |     | $     |

__________________

(1) The assumed combined public offering price is $1.30 per share of Common Stock and accompanying Common Warrants and $1.2999 per Pre-Funded Warrant and accompanying Common Warrants.

(2) Does not include proceeds from the exercise of the Pre-Funded Warrants or Common W